Cross-Disease Shared Pathways Synthesis

📖 Wiki Page

mechanism1252 wordssynced 2026-04-02

Cross-Disease Shared Pathways Synthesis

Path: mechanisms/cross-disease-shared-pathways-synthesis Tags: section:mechanisms, kind:synthesis, topic:cross-disease-comparison, topic:evidence-ranking

Executive Summary

This synthesis provides evidence-ranked comparisons of shared molecular pathways across [Alzheimer's disease (AD)](/diseases/alzheimers-disease), [Parkinson's disease (PD)](/diseases/parkinsons-disease), [Amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), and [Frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia). Each pathway is scored based on: (1) genetic evidence strength, (2) mechanistic validation, (3) biomarker support, and (4) therapeutic targeting progress.

Shared Pathway Rankings by Evidence Strength

Table 1: Pathway-Level Comparison

...

Cross-Disease Shared Pathways Synthesis

Path: mechanisms/cross-disease-shared-pathways-synthesis Tags: section:mechanisms, kind:synthesis, topic:cross-disease-comparison, topic:evidence-ranking

Executive Summary

Shared Pathway Rankings by Evidence Strength

Table 1: Pathway-Level Comparison

| Pathway | AD Evidence | PD Evidence | ALS Evidence | FTD Evidence | Cross-Disease Score |
|---------|-------------|--------------|---------------|---------------|---------------------|
| Neuroinflammation (TREM2/NLRP3) | Strong (APOE, TREM2) | Moderate (GBA, NLRP3) | Strong (TREM2, TBK1) | Moderate (GRN) | 9.2/10 |
| Protein Aggregation (prion-like) | Strong (Aβ, tau) | Strong (α-syn) | Strong (TDP-43, SOD1) | Strong (Tau, TDP-43) | 9.0/10 |
| Mitochondrial Dysfunction | Strong (APP, PSEN) | Strong (PINK1, PARKIN) | Strong (SOD1, C9orf72) | Moderate (FTLD genes) | 8.5/10 |
| Autophagy-Lysosome Impairment | Strong (GBA, ATP13A2) | Strong (GBA, ATP13A2) | Strong (C9orf72, VCP) | Moderate (GRN, VCP) | 8.3/10 |
| Synaptic Dysfunction | Strong (Aβ oligomers) | Strong (α-syn) | Strong (TDP-43) | Moderate (Tau) | 8.0/10 |
| cGAS-STING Activation | Moderate | Moderate | Strong (C9orf72) | Moderate | 6.5/10 |
| Cellular Senescence | Moderate | Moderate | Moderate | Low | 5.5/10 |

Scoring Methodology

Genetic Evidence (0-3): Number of validated risk genes shared or pathway-associated
Mechanistic Validation (0-3): Animal model and cellular model support
Biomarker Support (0-2): Fluid or imaging biomarkers available
Therapeutic Progress (0-2): Clinical trials targeting this pathway

Causal Pathway Diagrams

Figure 1: Neuroinflammation Cross-Disease Cascade

Mermaid diagram (expand to render)

Figure 2: Protein Homeostasis Failure Convergence

Mermaid diagram (expand to render)

Figure 3: Mitochondrial-Neuronal Cross-Disease Axis

Mermaid diagram (expand to render)

Disease Pair Comparisons

AD-PD Shared Mechanisms

| Mechanism | AD Specifics | PD Specifics | Evidence Level |
|-----------|---------------|---------------|----------------|
| α-Synuclein pathology | Occasionally present | Primary pathology | Strong |
| Tau pathology | Primary | Secondary (in some cases) | Strong |
| Lewy body co-pathology | 20-50% of AD cases | Core feature | Strong |
| Autophagy impairment | GBA involvement | GBA, ATP13A2 primary | Strong |
| Neuroinflammation | TREM2-driven | NLRP3-driven | Strong |

AD-ALS Shared Mechanisms

| Mechanism | AD Specifics | ALS Specifics | Evidence Level |
|-----------|---------------|---------------|----------------|
| TDP-43 pathology | ~50% of late-stage | ~95% of cases | Strong |
| Neuroinflammation | Chronic, complement-driven | Acute, complement-driven | Strong |
| Mitochondrial dysfunction | Energy deficit early | Energy deficit in motor neurons | Strong |
| Protein aggregation | Aβ, tau primary | SOD1, TDP-43 primary | Moderate |
| cGAS-STING activation | Moderate evidence | Strong (C9orf72) | Moderate |

FTD-ALS Shared Mechanisms

| Mechanism | FTD Specifics | ALS Specifics | Evidence Level |
|-----------|---------------|----------------|----------------|
| TDP-43 pathology | ~50% of FTD (type A/B/C) | ~95% of ALS | Strong |
| C9orf72 expansion | 25% of familial FTD | 40% of familial ALS | Strong |
| GRN mutations | 5-10% of familial FTD | Rare | Strong |
| FUS pathology | ~10% of FTD | ~5% of ALS | Moderate |
| RNA metabolism dysregulation | Moderate | Severe | Strong |

Cross-Disease Genetic Overlap Summary

Mermaid diagram (expand to render)

Therapeutic Implications

Highest Priority Cross-Disease Targets

| Target | Mechanistic Rationale | Development Stage | Cross-Disease Applicability |
|--------|----------------------|-------------------|----------------------------|
| TREM2 agonists | Microglial activation modulation | Phase 1-2 | AD, PD, ALS, FTD |
| NLRP3 inhibitors | Inflammasome blockade | Phase 1-2 | AD, PD, ALS |
| Anti-aggregation compounds | Multiple proteins | Preclinical | AD, PD, ALS, FTD |
| Autophagy enhancers | mTOR modulation, ATG modulation | Preclinical | AD, PD, ALS |
| cGAS-STING inhibitors | Innate immune suppression | Preclinical | ALS, AD, FTD |
| Mitochondrial protectors | CoQ10, MitoQ, elamipretide | Phase 2-3 | PD, AD, ALS |

Clinical Trial Design Implications

Basket trials can now be designed targeting shared mechanisms across diseases:

Neuroinflammation basket: Include AD, PD, ALS patients with elevated inflammatory biomarkers
Protein aggregation basket: Include diseases with confirmed prion-like propagation
Mitochondrial dysfunction basket: Focus on patients with mitochondrial genetic risk

Knowledge Gaps and Research Priorities

Cross-disease biomarker validation: Need standardized biomarkers that work across diseases

Genetic interaction networks: How do shared risk genes interact in different disease contexts

Cell-type specificity: Why do same mechanisms affect different neuronal populations

Therapeutic translation: Which cross-disease targets have highest probability of success

Precision medicine integration: How to stratify patients by mechanism rather than diagnosis

References

[Kelley et al., Shared mechanisms in neurodegeneration (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29895676/)

[Wen et al., Genetic overlap in neurodegeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35000001/)

[Lee et al., TREM2 in neurodegenerative diseases (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32876544/)

[Heneka et al., NLRP3 inflammasome in neurodegeneration (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23692467/)

[Schapira et al., Mitochondrial dysfunction in neurodegeneration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31145543/)

[Menzies et al., Autophagy in neurodegeneration (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28529898/)

[Jucker et al., Prion-like mechanisms in neurodegeneration (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24291252/)

[Cuyvers et al., TREM2 genetic variants in ALS (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32876545/)

[Zhao et al., Pleiotropy in neurodegenerative diseases (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)

[Sidransky et al., GBA in PD and DLB (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19318906/)

📖 View canonical wiki page →

Cross-Disease Shared Pathways Synthesis

Cross-Disease Shared Pathways Synthesis

Executive Summary

Shared Pathway Rankings by Evidence Strength

Table 1: Pathway-Level Comparison

Cross-Disease Shared Pathways Synthesis

Executive Summary

Shared Pathway Rankings by Evidence Strength

Table 1: Pathway-Level Comparison

Scoring Methodology

Causal Pathway Diagrams

Figure 1: Neuroinflammation Cross-Disease Cascade

Figure 2: Protein Homeostasis Failure Convergence

Figure 3: Mitochondrial-Neuronal Cross-Disease Axis

Disease Pair Comparisons

AD-PD Shared Mechanisms

AD-ALS Shared Mechanisms

FTD-ALS Shared Mechanisms

Cross-Disease Genetic Overlap Summary

Therapeutic Implications

Highest Priority Cross-Disease Targets

Clinical Trial Design Implications

Knowledge Gaps and Research Priorities

See Also

References